3 Bullish Signs From a Struggling Biotech
One of the presenters at the JPMorgan conference yesterday was the biotech Dendreon , a stock that gets a lot of attention from readers of Fool.com. In this video, Motley Fool health care bureau chief Brenton Flynn discusses three bullish points from the company's presentation. He gives us areas where the company is growing, tells us how it is increasing awareness around its treatment -- which may buoy all players in that sector -- and talks about some progress that the company has made in its restructuring efforts.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. Make sure you start 2013 with a bang and get the inside scoop on what Motley Fool Superinvestor David Gardner will be buying this year. He's crushed the market in his Stock Advisor and Rule Breakers portfolios for years, and now I invite you to a personal tour of his flagship stock picking service: Supernova. Just click here now for instant access.
The article 3 Bullish Signs From a Struggling Biotech originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.